D. Kaufman

发表

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

J. Lunceford, Chunsheng Zhang, T. Mcclanahan, 2018, Science.

Efficient Generation of Mucosal and Systemic Antigen-Specific CD8+ T-Cell Responses following Pulmonary DNA Immunization

N. Letvin, D. Kaufman, M. Bivas-Benita, 2010, Journal of Virology.

Systematic evaluation of immune regulation and modulation

H. Kong, F. Marincola, B. Seliger, 2017, Journal of Immunotherapy for Cancer.

Abstract CT115: Phase 1bKEYNOTE 200 (STORM study):A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients

C. Rudin, E. Schmidt, A. Melcher, 2017 .

Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients.

C. Rudin, E. Schmidt, H. Pandha, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

Translational Mini‐Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine‐elicited mucosal immunity

D. Kaufman, D. Barouch, DanH. Barouch, 2009, Clinical and experimental immunology.

Cell Responses T + Elicited CD8 - Help for Adenovirus Vector T Cell + Longitudinal Requirement for CD4

D. Kaufman, N. Provine, E. Borducchi, 2014 .

Longitudinal Requirement for CD4+ T Cell Help for Adenovirus Vector–Elicited CD8+ T Cell Responses

D. Kaufman, D. Barouch, N. Provine, 2014, The Journal of Immunology.

Stimulus-dependent Synergism of the Antiapoptotic Tumor Necrosis Factor Receptor–associated Factor 2 (TRAF2) and Nuclear Factor κB Pathways

Soo Young Lee, D. Kaufman, M. Boothby, 1998, The Journal of experimental medicine.

Stimulus-dependent of the Antiapoptotic Tumor Necrosis Factor Receptor–associated Factor 2 (TRAF2) and Nuclear Factor (cid:107) B Pathways

D. Kaufman, M. Boothby, Soo-Young Lee, 1998 .

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

F. Marincola, P. Ascierto, M. Atkins, 2020, Journal for ImmunoTherapy of Cancer.

Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice

J. Héraud, D. Kaufman, M. Havenga, 2008, Journal of Virology.

Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

W. Wilson, J. Gribben, D. Esseltine, 2000, Cancer journal.

Vaccine-Elicited Gastrointestinal Immunity Vitamin A Deficiency Impairs

D. Kaufman, D. Barouch, E. Villablanca, 2011 .

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

J. Malvehy, R. Dummer, J. Kirkwood, 2015, Journal of Immunotherapy for Cancer.

Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8+ T Lymphocytes

D. Kaufman, M. Bivas-Benita, Nathaniel L. Simmons, 2010, Journal of Virology.

Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafﬁcking of Vaccine-Elicited CD8 (cid:1) T Lymphocytes (cid:1)

D. Kaufman, M. Bivas-Benita, Nathaniel L. Simmons, 2010 .

J. Lunceford, T. Mcclanahan, M. Ayers, 2017, The Journal of clinical investigation.

J. Lunceford, T. Mcclanahan, M. Ayers, 2019 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.

T. Choueiri, E. Plimack, G. Sonpavde, 2015 .

Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection in vivo

A. Trkola, H. Günthard, R. Weber, 2002, Antiviral therapy.

Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys.

S. Self, D. Kaufman, D. Barouch, 2012, Vaccine.

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors.

D. Kaufman, S. Hu-Lieskovan, Z. Wainberg, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy

T. Mcclanahan, M. Ayers, R. Cristescu, 2018, Clinical Cancer Research.

Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors

B. Pulendran, S. Kasturi, D. Kaufman, 2010, Journal of Virology.

Response to Comment on “Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination”

D. Kaufman, D. Barouch, 2009, The Journal of Immunology.

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

David C. Smith, D. Kaufman, A. Balmanoukian, 2015, Journal of Immunotherapy for Cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.

F. Hodi, J. Schellens, D. Kaufman, 2016 .

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

David C. Smith, D. Kaufman, A. Balmanoukian, 2016 .

Vitamin A Deficiency Impairs Vaccine-Elicited Gastrointestinal Immunity

D. Kaufman, J. Mora, D. Barouch, 2011, The Journal of Immunology.

Genomic biomarkers in relation to PD-1 checkpoint blockade response.

J. Lunceford, Chunsheng Zhang, T. Mcclanahan, 2018 .

Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination1

K. Mansfield, D. Kaufman, M. Havenga, 2008, The Journal of Immunology.

SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art

Pier Federico Gherardini, Marta Luksza, Bernard A. Fox, 2018, Journal of Immunotherapy for Cancer.

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

J. Malvehy, R. Dummer, J. Kirkwood, 2015 .

J. Lunceford, T. Mcclanahan, M. Ayers, 2017 .

A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.

R. Dummer, J. Kirkwood, A. Ribas, 2015 .

LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.

D. Kaufman, S. Reed, D. Kaufman, 1998, Journal of immunology.

Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab.

J. Lunceford, T. Mcclanahan, M. Ayers, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.